secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xilio Therapeutics, Inc. (XLO)
CIK:        0001840233
Form:       8-K
Filed at:   2025-06-02T23:59:59+00:00
Accession:  0001193125-25-132710
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program
--------------------------------------------------------------------------------

- 26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.
- Differentiated safety: only 7% colitis (3/44), low discontinuation (5%); combination well-tolerated.
- Patient with liver metastasis from Phase 1C on treatment >14 months; 150mg Q6W dose cleared and cohort enrolling.
- Xilio seeking partnership for vilastobart to accelerate development; additional data expected H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/0001193125-25-132710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840233/000119312525132710/d91295d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-132710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer